2020 Autism spectrum disorders (ASD) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Autism spectrum disorders (ASD) pipeline report presents a comprehensive overview of the research and development of Autism spectrum disorders (ASD) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Two drugs in Research phase, 13 drugs in Pre-clinical phase, four drugs in Phase 1, seven drugs in Phase 2, four drugs in Phase 3 and one drug in pre-registration
As of February 2020, the Autism spectrum disorders (ASD) pipeline remains robust with 33 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Autism spectrum disorders (ASD) treatment. Diverse types of targeted therapies are being explored through clinical trials including 5-HT2A receptor antagonist; AMPA receptor agonists; Cannabinoid receptor modulators; Dopamine D2 /D3/D4 receptor partial agonists; Dopaminergic cell replacements; Fatty acid amide hydrolase inhibitors; GABA A alpha 5 receptor modulators; histamine agonist; lipopolysaccharides (LPS) antagonist; Melatonin receptor agonists; Metabotropic glutamate receptor 5 modulators; NAV1.2 voltage-gated sodium channel expression stimulants; NF E2 related factor 2 stimulants; opioid receptor antagonist; oxytocin receptor agonist; P70 S6 kinase inhibitor; Serotonin 1A/2A receptor partial agonists; Sodium-potassium-chloride symporter inhibitors; Telomeric 22q13 Monosomy Syndrome; Tyrosine hydroxylase inhibitors; Vasopressin 1 receptor antagonists.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Autism spectrum disorders (ASD) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Autism spectrum disorders (ASD) pipeline drugs profiled in the report include- Biologics for Autism , GABA A alpha 5 receptor modulators for Autistic disorder, histamine dihydrochloride, BTRX-323511, NurOwn, CB0306, levoleucovorin, CM-AT, IRT-103 (naltrexone), EPGN1370, SFX-01, balovaptan, RG-7816, FIN-211, GWP42006 (CBDV), IMM-124E, cannabidiol , ITI-007 (lumateperon), JNJ-5279, Melatonin, bumetanide, OPN-300 (oxytocin), Small Molecule for Autism, CX717, brilaroxazine, RCUR-313, RCUR-SMP, Antibodies for Autism , GPCR modulators(HTL0022562), SM-13496 (lurasidone), Stem Cell Therapy for CNS Disorders, Autism, L1-79, NNZ-2591, ZELDA
As of February 2020, the Autism spectrum disorders (ASD) pipeline remains robust with 33 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Autism spectrum disorders (ASD) treatment. Diverse types of targeted therapies are being explored through clinical trials including 5-HT2A receptor antagonist; AMPA receptor agonists; Cannabinoid receptor modulators; Dopamine D2 /D3/D4 receptor partial agonists; Dopaminergic cell replacements; Fatty acid amide hydrolase inhibitors; GABA A alpha 5 receptor modulators; histamine agonist; lipopolysaccharides (LPS) antagonist; Melatonin receptor agonists; Metabotropic glutamate receptor 5 modulators; NAV1.2 voltage-gated sodium channel expression stimulants; NF E2 related factor 2 stimulants; opioid receptor antagonist; oxytocin receptor agonist; P70 S6 kinase inhibitor; Serotonin 1A/2A receptor partial agonists; Sodium-potassium-chloride symporter inhibitors; Telomeric 22q13 Monosomy Syndrome; Tyrosine hydroxylase inhibitors; Vasopressin 1 receptor antagonists.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Autism spectrum disorders (ASD) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Autism spectrum disorders (ASD) development
- Autism spectrum disorders (ASD) pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Autism spectrum disorders (ASD) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Autism spectrum disorders (ASD) pipeline candidates included
- Business overview and snapshot of all companies involved in Autism spectrum disorders (ASD) pipeline are included
- Latest market and pipeline developments are provided in the report
Autism spectrum disorders (ASD) pipeline drugs profiled in the report include- Biologics for Autism , GABA A alpha 5 receptor modulators for Autistic disorder, histamine dihydrochloride, BTRX-323511, NurOwn, CB0306, levoleucovorin, CM-AT, IRT-103 (naltrexone), EPGN1370, SFX-01, balovaptan, RG-7816, FIN-211, GWP42006 (CBDV), IMM-124E, cannabidiol , ITI-007 (lumateperon), JNJ-5279, Melatonin, bumetanide, OPN-300 (oxytocin), Small Molecule for Autism, CX717, brilaroxazine, RCUR-313, RCUR-SMP, Antibodies for Autism , GPCR modulators(HTL0022562), SM-13496 (lurasidone), Stem Cell Therapy for CNS Disorders, Autism, L1-79, NNZ-2591, ZELDA
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Autism spectrum disorders (ASD) Condition
2.3 Autism spectrum disorders (ASD) Pipeline Snapshot, 2020
2.4 Companies investing in Autism spectrum disorders (ASD) pipeline therapeutics
2.5 Phase wise Autism spectrum disorders (ASD) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Autism spectrum disorders (ASD) Pipeline Products
2.7 Route of Administration of Autism spectrum disorders (ASD) Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 4D Pharma Plc Overview, Contacts and ASD Pipeline Drugs
3.2 AgeneBio Inc Overview, Contacts and ASD Pipeline Drugs
3.3 BioHealthonomics Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Blackthorn Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.5 BrainStorm Cell Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Cennerv Pharma (S) Pte Ltd Overview, Contacts and ASD Pipeline Drugs
3.7 Cox Biosciences LLC Overview, Contacts and ASD Pipeline Drugs
3.8 Curemark LLC Overview, Contacts and ASD Pipeline Drugs
3.9 Cytocom Inc Overview, Contacts and ASD Pipeline Drugs
3.10 Epigen Biosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.11 Evgen Pharma Plc Overview, Contacts and ASD Pipeline Drugs
3.12 F. Hoffmann-La Roche Ltd Overview, Contacts and ASD Pipeline Drugs
3.13 Finch Therapeutics Overview, Contacts and ASD Pipeline Drugs
3.14 GW Pharmaceuticals Plc Overview, Contacts and ASD Pipeline Drugs
3.15 Immuron Ltd Overview, Contacts and ASD Pipeline Drugs
3.16 Insys Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.17 Intra-Cellular Therapies Inc Overview, Contacts and ASD Pipeline Drugs
3.18 Johnson & Johnson Overview, Contacts and ASD Pipeline Drugs
3.19 Neuren Pharmaceuticals Overview, Contacts and ASD Pipeline Drugs
3.20 Neurim Pharmaceuticals Ltd Overview, Contacts and ASD Pipeline Drugs
3.21 Neurochlore Overview, Contacts and ASD Pipeline Drugs
3.22 OptiNose US Inc Overview, Contacts and ASD Pipeline Drugs
3.23 Ovensa Inc Overview, Contacts and ASD Pipeline Drugs
3.24 RespireRx Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.25 Reviva Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.26 RogCon Inc Overview, Contacts and ASD Pipeline Drugs
3.27 Sengenics Overview, Contacts and ASD Pipeline Drugs
3.28 Sosei Heptares Overview, Contacts and ASD Pipeline Drugs
3.29 Sumitomo Dainippon Pharma Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.30 Translational Biosciences Overview, Contacts and ASD Pipeline Drugs
3.31 Yamo Pharmaceuticals LLC Overview, Contacts and ASD Pipeline Drugs
3.32 Zelda Therapeutics Pty Ltd Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 Biologics for Autism Drug Details
4.1.1 Biologics for Autism Current Status
4.1.2 Biologics for Autism Drug Overview
4.1.3 Biologics for Autism Mechanism of Action
4.1.4 Biologics for Autism Licensing/Collaboration Companies
4.1.5 Biologics for Autism Clinical Trials
4.2 GABA A alpha 5 receptor modulators for Autistic disorder Drug Details
4.2.1 GABA A alpha 5 receptor modulators for Autistic disorder Current Status
4.2.2 GABA A alpha 5 receptor modulators for Autistic disorder Drug Overview
4.2.3 GABA A alpha 5 receptor modulators for Autistic disorder Mechanism of Action
4.2.4 GABA A alpha 5 receptor modulators for Autistic disorder Licensing/Collaboration Companies
4.2.5 GABA A alpha 5 receptor modulators for Autistic disorder Clinical Trials
4.3 histamine dihydrochloride Drug Details
4.3.1 histamine dihydrochloride Current Status
4.3.2 histamine dihydrochloride Drug Overview
4.3.3 histamine dihydrochloride Mechanism of Action
4.3.4 histamine dihydrochloride Licensing/Collaboration Companies
4.3.5 histamine dihydrochloride Clinical Trials
4.4 BTRX-323511 Drug Details
4.4.1 BTRX-323511 Current Status
4.4.2 BTRX-323511 Drug Overview
4.4.3 BTRX-323511 Mechanism of Action
4.4.4 BTRX-323511 Licensing/Collaboration Companies
4.4.5 BTRX-323511 Clinical Trials
4.5 NurOwn Drug Details
4.5.1 NurOwn Current Status
4.5.2 NurOwn Drug Overview
4.5.3 NurOwn Mechanism of Action
4.5.4 NurOwn Licensing/Collaboration Companies
4.5.5 NurOwn Clinical Trials
4.6 CB0306 Drug Details
4.6.1 CB0306 Current Status
4.6.2 CB0306 Drug Overview
4.6.3 CB0306 Mechanism of Action
4.6.4 CB0306 Licensing/Collaboration Companies
4.6.5 CB0306 Clinical Trials
4.7 levoleucovorin Drug Details
4.7.1 levoleucovorin Current Status
4.7.2 levoleucovorin Drug Overview
4.7.3 levoleucovorin Mechanism of Action
4.7.4 levoleucovorin Licensing/Collaboration Companies
4.7.5 levoleucovorin Clinical Trials
4.8 CM-AT Drug Details
4.8.1 CM-AT Current Status
4.8.2 CM-AT Drug Overview
4.8.3 CM-AT Mechanism of Action
4.8.4 CM-AT Licensing/Collaboration Companies
4.8.5 CM-AT Clinical Trials
4.9 IRT-103 (naltrexone) Drug Details
4.9.1 IRT-103 (naltrexone) Current Status
4.9.2 IRT-103 (naltrexone) Drug Overview
4.9.3 IRT-103 (naltrexone) Mechanism of Action
4.9.4 IRT-103 (naltrexone) Licensing/Collaboration Companies
4.9.5 IRT-103 (naltrexone) Clinical Trials
4.10 EPGN1370 Drug Details
4.10.1 EPGN1370 Current Status
4.10.2 EPGN1370 Drug Overview
4.10.3 EPGN1370 Mechanism of Action
4.10.4 EPGN1370 Licensing/Collaboration Companies
4.10.5 EPGN1370 Clinical Trials
4.11 SFX-01 Drug Details
4.11.1 SFX-01 Current Status
4.11.2 SFX-01 Drug Overview
4.11.3 SFX-01 Mechanism of Action
4.11.4 SFX-01 Licensing/Collaboration Companies
4.11.5 SFX-01 Clinical Trials
4.12 balovaptan Drug Details
4.12.1 balovaptan Current Status
4.12.2 balovaptan Drug Overview
4.12.3 balovaptan Mechanism of Action
4.12.4 balovaptan Licensing/Collaboration Companies
4.12.5 balovaptan Clinical Trials
4.13 RG-7816 Drug Details
4.13.1 RG-7816 Current Status
4.13.2 RG-7816 Drug Overview
4.13.3 RG-7816 Mechanism of Action
4.13.4 RG-7816 Licensing/Collaboration Companies
4.13.5 RG-7816 Clinical Trials
4.14 FIN-211 Drug Details
4.14.1 FIN-211 Current Status
4.14.2 FIN-211 Drug Overview
4.14.3 FIN-211 Mechanism of Action
4.14.4 FIN-211 Licensing/Collaboration Companies
4.14.5 FIN-211 Clinical Trials
4.15 GWP42006 (CBDV) Drug Details
4.15.1 GWP42006 (CBDV) Current Status
4.15.2 GWP42006 (CBDV) Drug Overview
4.15.3 GWP42006 (CBDV) Mechanism of Action
4.15.4 GWP42006 (CBDV) Licensing/Collaboration Companies
4.15.5 GWP42006 (CBDV) Clinical Trials
4.16 IMM-124E Drug Details
4.16.1 IMM-124E Current Status
4.16.2 IMM-124E Drug Overview
4.16.3 IMM-124E Mechanism of Action
4.16.4 IMM-124E Licensing/Collaboration Companies
4.16.5 IMM-124E Clinical Trials
4.17 cannabidiol Drug Details
4.17.1 cannabidiol Current Status
4.17.2 cannabidiol Drug Overview
4.17.3 cannabidiol Mechanism of Action
4.17.4 cannabidiol Licensing/Collaboration Companies
4.17.5 cannabidiol Clinical Trials
4.18 ITI-007 (lumateperon) Drug Details
4.18.1 ITI-007 (lumateperon) Current Status
4.18.2 ITI-007 (lumateperon) Drug Overview
4.18.3 ITI-007 (lumateperon) Mechanism of Action
4.18.4 ITI-007 (lumateperon) Licensing/Collaboration Companies
4.18.5 ITI-007 (lumateperon) Clinical Trials
4.19 JNJ-5279 Drug Details
4.19.1 JNJ-5279 Current Status
4.19.2 JNJ-5279 Drug Overview
4.19.3 JNJ-5279 Mechanism of Action
4.19.4 JNJ-5279 Licensing/Collaboration Companies
4.19.5 JNJ-5279 Clinical Trials
4.20 Melatonin Drug Details
4.20.1 Melatonin Current Status
4.20.2 Melatonin Drug Overview
4.20.3 Melatonin Mechanism of Action
4.20.4 Melatonin Licensing/Collaboration Companies
4.20.5 Melatonin Clinical Trials
4.21 bumetanide Drug Details
4.21.1 bumetanide Current Status
4.21.2 bumetanide Drug Overview
4.21.3 bumetanide Mechanism of Action
4.21.4 bumetanide Licensing/Collaboration Companies
4.21.5 bumetanide Clinical Trials
4.22 OPN-300 (oxytocin) Drug Details
4.22.1 OPN-300 (oxytocin) Current Status
4.22.2 OPN-300 (oxytocin) Drug Overview
4.22.3 OPN-300 (oxytocin) Mechanism of Action
4.22.4 OPN-300 (oxytocin) Licensing/Collaboration Companies
4.22.5 OPN-300 (oxytocin) Clinical Trials
4.23 Small Molecule for Autism Drug Details
4.23.1 Small Molecule for Autism Current Status
4.23.2 Small Molecule for Autism Drug Overview
4.23.3 Small Molecule for Autism Mechanism of Action
4.23.4 Small Molecule for Autism Licensing/Collaboration Companies
4.23.5 Small Molecule for Autism Clinical Trials
4.24 CX717 Drug Details
4.24.1 CX717 Current Status
4.24.2 CX717 Drug Overview
4.24.3 CX717 Mechanism of Action
4.24.4 CX717 Licensing/Collaboration Companies
4.24.5 CX717 Clinical Trials
4.25 brilaroxazine Drug Details
4.25.1 brilaroxazine Current Status
4.25.2 brilaroxazine Drug Overview
4.25.3 brilaroxazine Mechanism of Action
4.25.4 brilaroxazine Licensing/Collaboration Companies
4.25.5 brilaroxazine Clinical Trials
4.26 RCUR-313 Drug Details
4.26.1 RCUR-313 Current Status
4.26.2 RCUR-313 Drug Overview
4.26.3 RCUR-313 Mechanism of Action
4.26.4 RCUR-313 Licensing/Collaboration Companies
4.26.5 RCUR-313 Clinical Trials
4.27 RCUR-SMP Drug Details
4.27.1 RCUR-SMP Current Status
4.27.2 RCUR-SMP Drug Overview
4.27.3 RCUR-SMP Mechanism of Action
4.27.4 RCUR-SMP Licensing/Collaboration Companies
4.27.5 RCUR-SMP Clinical Trials
4.28 Antibodies for Autism Drug Details
4.28.1 Antibodies for Autism Current Status
4.28.2 Antibodies for Autism Drug Overview
4.28.3 Antibodies for Autism Mechanism of Action
4.28.4 Antibodies for Autism Licensing/Collaboration Companies
4.28.5 Antibodies for Autism Clinical Trials
4.29 GPCR modulators(HTL0022562) Drug Details
4.29.1 GPCR modulators(HTL0022562) Current Status
4.29.2 GPCR modulators(HTL0022562) Drug Overview
4.29.3 GPCR modulators(HTL0022562) Mechanism of Action
4.29.4 GPCR modulators(HTL0022562) Licensing/Collaboration Companies
4.29.5 GPCR modulators(HTL0022562) Clinical Trials
4.30 SM-13496 (lurasidone) Drug Details
4.30.1 SM-13496 (lurasidone) Current Status
4.30.2 SM-13496 (lurasidone) Drug Overview
4.30.3 SM-13496 (lurasidone) Mechanism of Action
4.30.4 SM-13496 (lurasidone) Licensing/Collaboration Companies
4.30.5 SM-13496 (lurasidone) Clinical Trials
4.31 Stem Cell Therapy for CNS Disorders, Autism Drug Details
4.31.1 Stem Cell Therapy for CNS Disorders, Autism Current Status
4.31.2 Stem Cell Therapy for CNS Disorders, Autism Drug Overview
4.31.3 Stem Cell Therapy for CNS Disorders, Autism Mechanism of Action
4.31.4 Stem Cell Therapy for CNS Disorders, Autism Licensing/Collaboration Companies
4.31.5 Stem Cell Therapy for CNS Disorders, Autism Clinical Trials
4.32 L1-79 Drug Details
4.32.1 L1-79 Current Status
4.32.2 L1-79 Drug Overview
4.32.3 L1-79 Mechanism of Action
4.32.4 L1-79 Licensing/Collaboration Companies
4.32.5 L1-79 Clinical Trials
4.33 NNZ-2591 Drug Details
4.33.1 NNZ-2591 Current Status
4.33.2 NNZ-2591 Drug Overview
4.33.3 NNZ-2591 Mechanism of Action
4.33.4 NNZ-2591 Licensing/Collaboration Companies
4.33.5 NNZ-2591 Clinical Trials
5. LATEST AUTISM SPECTRUM DISORDERS (ASD) PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Autism spectrum disorders (ASD) Condition
2.3 Autism spectrum disorders (ASD) Pipeline Snapshot, 2020
2.4 Companies investing in Autism spectrum disorders (ASD) pipeline therapeutics
2.5 Phase wise Autism spectrum disorders (ASD) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Autism spectrum disorders (ASD) Pipeline Products
2.7 Route of Administration of Autism spectrum disorders (ASD) Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 4D Pharma Plc Overview, Contacts and ASD Pipeline Drugs
3.2 AgeneBio Inc Overview, Contacts and ASD Pipeline Drugs
3.3 BioHealthonomics Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Blackthorn Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.5 BrainStorm Cell Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Cennerv Pharma (S) Pte Ltd Overview, Contacts and ASD Pipeline Drugs
3.7 Cox Biosciences LLC Overview, Contacts and ASD Pipeline Drugs
3.8 Curemark LLC Overview, Contacts and ASD Pipeline Drugs
3.9 Cytocom Inc Overview, Contacts and ASD Pipeline Drugs
3.10 Epigen Biosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.11 Evgen Pharma Plc Overview, Contacts and ASD Pipeline Drugs
3.12 F. Hoffmann-La Roche Ltd Overview, Contacts and ASD Pipeline Drugs
3.13 Finch Therapeutics Overview, Contacts and ASD Pipeline Drugs
3.14 GW Pharmaceuticals Plc Overview, Contacts and ASD Pipeline Drugs
3.15 Immuron Ltd Overview, Contacts and ASD Pipeline Drugs
3.16 Insys Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.17 Intra-Cellular Therapies Inc Overview, Contacts and ASD Pipeline Drugs
3.18 Johnson & Johnson Overview, Contacts and ASD Pipeline Drugs
3.19 Neuren Pharmaceuticals Overview, Contacts and ASD Pipeline Drugs
3.20 Neurim Pharmaceuticals Ltd Overview, Contacts and ASD Pipeline Drugs
3.21 Neurochlore Overview, Contacts and ASD Pipeline Drugs
3.22 OptiNose US Inc Overview, Contacts and ASD Pipeline Drugs
3.23 Ovensa Inc Overview, Contacts and ASD Pipeline Drugs
3.24 RespireRx Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.25 Reviva Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.26 RogCon Inc Overview, Contacts and ASD Pipeline Drugs
3.27 Sengenics Overview, Contacts and ASD Pipeline Drugs
3.28 Sosei Heptares Overview, Contacts and ASD Pipeline Drugs
3.29 Sumitomo Dainippon Pharma Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.30 Translational Biosciences Overview, Contacts and ASD Pipeline Drugs
3.31 Yamo Pharmaceuticals LLC Overview, Contacts and ASD Pipeline Drugs
3.32 Zelda Therapeutics Pty Ltd Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 Biologics for Autism Drug Details
4.1.1 Biologics for Autism Current Status
4.1.2 Biologics for Autism Drug Overview
4.1.3 Biologics for Autism Mechanism of Action
4.1.4 Biologics for Autism Licensing/Collaboration Companies
4.1.5 Biologics for Autism Clinical Trials
4.2 GABA A alpha 5 receptor modulators for Autistic disorder Drug Details
4.2.1 GABA A alpha 5 receptor modulators for Autistic disorder Current Status
4.2.2 GABA A alpha 5 receptor modulators for Autistic disorder Drug Overview
4.2.3 GABA A alpha 5 receptor modulators for Autistic disorder Mechanism of Action
4.2.4 GABA A alpha 5 receptor modulators for Autistic disorder Licensing/Collaboration Companies
4.2.5 GABA A alpha 5 receptor modulators for Autistic disorder Clinical Trials
4.3 histamine dihydrochloride Drug Details
4.3.1 histamine dihydrochloride Current Status
4.3.2 histamine dihydrochloride Drug Overview
4.3.3 histamine dihydrochloride Mechanism of Action
4.3.4 histamine dihydrochloride Licensing/Collaboration Companies
4.3.5 histamine dihydrochloride Clinical Trials
4.4 BTRX-323511 Drug Details
4.4.1 BTRX-323511 Current Status
4.4.2 BTRX-323511 Drug Overview
4.4.3 BTRX-323511 Mechanism of Action
4.4.4 BTRX-323511 Licensing/Collaboration Companies
4.4.5 BTRX-323511 Clinical Trials
4.5 NurOwn Drug Details
4.5.1 NurOwn Current Status
4.5.2 NurOwn Drug Overview
4.5.3 NurOwn Mechanism of Action
4.5.4 NurOwn Licensing/Collaboration Companies
4.5.5 NurOwn Clinical Trials
4.6 CB0306 Drug Details
4.6.1 CB0306 Current Status
4.6.2 CB0306 Drug Overview
4.6.3 CB0306 Mechanism of Action
4.6.4 CB0306 Licensing/Collaboration Companies
4.6.5 CB0306 Clinical Trials
4.7 levoleucovorin Drug Details
4.7.1 levoleucovorin Current Status
4.7.2 levoleucovorin Drug Overview
4.7.3 levoleucovorin Mechanism of Action
4.7.4 levoleucovorin Licensing/Collaboration Companies
4.7.5 levoleucovorin Clinical Trials
4.8 CM-AT Drug Details
4.8.1 CM-AT Current Status
4.8.2 CM-AT Drug Overview
4.8.3 CM-AT Mechanism of Action
4.8.4 CM-AT Licensing/Collaboration Companies
4.8.5 CM-AT Clinical Trials
4.9 IRT-103 (naltrexone) Drug Details
4.9.1 IRT-103 (naltrexone) Current Status
4.9.2 IRT-103 (naltrexone) Drug Overview
4.9.3 IRT-103 (naltrexone) Mechanism of Action
4.9.4 IRT-103 (naltrexone) Licensing/Collaboration Companies
4.9.5 IRT-103 (naltrexone) Clinical Trials
4.10 EPGN1370 Drug Details
4.10.1 EPGN1370 Current Status
4.10.2 EPGN1370 Drug Overview
4.10.3 EPGN1370 Mechanism of Action
4.10.4 EPGN1370 Licensing/Collaboration Companies
4.10.5 EPGN1370 Clinical Trials
4.11 SFX-01 Drug Details
4.11.1 SFX-01 Current Status
4.11.2 SFX-01 Drug Overview
4.11.3 SFX-01 Mechanism of Action
4.11.4 SFX-01 Licensing/Collaboration Companies
4.11.5 SFX-01 Clinical Trials
4.12 balovaptan Drug Details
4.12.1 balovaptan Current Status
4.12.2 balovaptan Drug Overview
4.12.3 balovaptan Mechanism of Action
4.12.4 balovaptan Licensing/Collaboration Companies
4.12.5 balovaptan Clinical Trials
4.13 RG-7816 Drug Details
4.13.1 RG-7816 Current Status
4.13.2 RG-7816 Drug Overview
4.13.3 RG-7816 Mechanism of Action
4.13.4 RG-7816 Licensing/Collaboration Companies
4.13.5 RG-7816 Clinical Trials
4.14 FIN-211 Drug Details
4.14.1 FIN-211 Current Status
4.14.2 FIN-211 Drug Overview
4.14.3 FIN-211 Mechanism of Action
4.14.4 FIN-211 Licensing/Collaboration Companies
4.14.5 FIN-211 Clinical Trials
4.15 GWP42006 (CBDV) Drug Details
4.15.1 GWP42006 (CBDV) Current Status
4.15.2 GWP42006 (CBDV) Drug Overview
4.15.3 GWP42006 (CBDV) Mechanism of Action
4.15.4 GWP42006 (CBDV) Licensing/Collaboration Companies
4.15.5 GWP42006 (CBDV) Clinical Trials
4.16 IMM-124E Drug Details
4.16.1 IMM-124E Current Status
4.16.2 IMM-124E Drug Overview
4.16.3 IMM-124E Mechanism of Action
4.16.4 IMM-124E Licensing/Collaboration Companies
4.16.5 IMM-124E Clinical Trials
4.17 cannabidiol Drug Details
4.17.1 cannabidiol Current Status
4.17.2 cannabidiol Drug Overview
4.17.3 cannabidiol Mechanism of Action
4.17.4 cannabidiol Licensing/Collaboration Companies
4.17.5 cannabidiol Clinical Trials
4.18 ITI-007 (lumateperon) Drug Details
4.18.1 ITI-007 (lumateperon) Current Status
4.18.2 ITI-007 (lumateperon) Drug Overview
4.18.3 ITI-007 (lumateperon) Mechanism of Action
4.18.4 ITI-007 (lumateperon) Licensing/Collaboration Companies
4.18.5 ITI-007 (lumateperon) Clinical Trials
4.19 JNJ-5279 Drug Details
4.19.1 JNJ-5279 Current Status
4.19.2 JNJ-5279 Drug Overview
4.19.3 JNJ-5279 Mechanism of Action
4.19.4 JNJ-5279 Licensing/Collaboration Companies
4.19.5 JNJ-5279 Clinical Trials
4.20 Melatonin Drug Details
4.20.1 Melatonin Current Status
4.20.2 Melatonin Drug Overview
4.20.3 Melatonin Mechanism of Action
4.20.4 Melatonin Licensing/Collaboration Companies
4.20.5 Melatonin Clinical Trials
4.21 bumetanide Drug Details
4.21.1 bumetanide Current Status
4.21.2 bumetanide Drug Overview
4.21.3 bumetanide Mechanism of Action
4.21.4 bumetanide Licensing/Collaboration Companies
4.21.5 bumetanide Clinical Trials
4.22 OPN-300 (oxytocin) Drug Details
4.22.1 OPN-300 (oxytocin) Current Status
4.22.2 OPN-300 (oxytocin) Drug Overview
4.22.3 OPN-300 (oxytocin) Mechanism of Action
4.22.4 OPN-300 (oxytocin) Licensing/Collaboration Companies
4.22.5 OPN-300 (oxytocin) Clinical Trials
4.23 Small Molecule for Autism Drug Details
4.23.1 Small Molecule for Autism Current Status
4.23.2 Small Molecule for Autism Drug Overview
4.23.3 Small Molecule for Autism Mechanism of Action
4.23.4 Small Molecule for Autism Licensing/Collaboration Companies
4.23.5 Small Molecule for Autism Clinical Trials
4.24 CX717 Drug Details
4.24.1 CX717 Current Status
4.24.2 CX717 Drug Overview
4.24.3 CX717 Mechanism of Action
4.24.4 CX717 Licensing/Collaboration Companies
4.24.5 CX717 Clinical Trials
4.25 brilaroxazine Drug Details
4.25.1 brilaroxazine Current Status
4.25.2 brilaroxazine Drug Overview
4.25.3 brilaroxazine Mechanism of Action
4.25.4 brilaroxazine Licensing/Collaboration Companies
4.25.5 brilaroxazine Clinical Trials
4.26 RCUR-313 Drug Details
4.26.1 RCUR-313 Current Status
4.26.2 RCUR-313 Drug Overview
4.26.3 RCUR-313 Mechanism of Action
4.26.4 RCUR-313 Licensing/Collaboration Companies
4.26.5 RCUR-313 Clinical Trials
4.27 RCUR-SMP Drug Details
4.27.1 RCUR-SMP Current Status
4.27.2 RCUR-SMP Drug Overview
4.27.3 RCUR-SMP Mechanism of Action
4.27.4 RCUR-SMP Licensing/Collaboration Companies
4.27.5 RCUR-SMP Clinical Trials
4.28 Antibodies for Autism Drug Details
4.28.1 Antibodies for Autism Current Status
4.28.2 Antibodies for Autism Drug Overview
4.28.3 Antibodies for Autism Mechanism of Action
4.28.4 Antibodies for Autism Licensing/Collaboration Companies
4.28.5 Antibodies for Autism Clinical Trials
4.29 GPCR modulators(HTL0022562) Drug Details
4.29.1 GPCR modulators(HTL0022562) Current Status
4.29.2 GPCR modulators(HTL0022562) Drug Overview
4.29.3 GPCR modulators(HTL0022562) Mechanism of Action
4.29.4 GPCR modulators(HTL0022562) Licensing/Collaboration Companies
4.29.5 GPCR modulators(HTL0022562) Clinical Trials
4.30 SM-13496 (lurasidone) Drug Details
4.30.1 SM-13496 (lurasidone) Current Status
4.30.2 SM-13496 (lurasidone) Drug Overview
4.30.3 SM-13496 (lurasidone) Mechanism of Action
4.30.4 SM-13496 (lurasidone) Licensing/Collaboration Companies
4.30.5 SM-13496 (lurasidone) Clinical Trials
4.31 Stem Cell Therapy for CNS Disorders, Autism Drug Details
4.31.1 Stem Cell Therapy for CNS Disorders, Autism Current Status
4.31.2 Stem Cell Therapy for CNS Disorders, Autism Drug Overview
4.31.3 Stem Cell Therapy for CNS Disorders, Autism Mechanism of Action
4.31.4 Stem Cell Therapy for CNS Disorders, Autism Licensing/Collaboration Companies
4.31.5 Stem Cell Therapy for CNS Disorders, Autism Clinical Trials
4.32 L1-79 Drug Details
4.32.1 L1-79 Current Status
4.32.2 L1-79 Drug Overview
4.32.3 L1-79 Mechanism of Action
4.32.4 L1-79 Licensing/Collaboration Companies
4.32.5 L1-79 Clinical Trials
4.33 NNZ-2591 Drug Details
4.33.1 NNZ-2591 Current Status
4.33.2 NNZ-2591 Drug Overview
4.33.3 NNZ-2591 Mechanism of Action
4.33.4 NNZ-2591 Licensing/Collaboration Companies
4.33.5 NNZ-2591 Clinical Trials
5. LATEST AUTISM SPECTRUM DISORDERS (ASD) PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
